A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
Clinical trial NCT01859026 · COMPLETED
Trial details
- NCT number
- NCT01859026
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2013-12-30
- Primary completion
- 2019-08-22
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.